Orlistat, an intestinal lipase inhibitor, and other new satiety-inducing drugs, such as liraglutide (high-dose GLP1 receptor agonist), lorcaserin (5-HT2c serotonin receptor agonist) and combinations of phentermine-topiramate or bupropion-naltrexone have demonstrated a great potential in T2DM treatment [68]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.